Phenotype of MCL cells derived from patients with MCL and cell lines
| MFIR . | MCL patients (n = 6) . | SP-53 . | MINO . | JeKo-1 . | Granta 519 . |
|---|---|---|---|---|---|
| CD44 | 42.5 ± 9.5 | 64.5 | 39.0 | 4.2 | 47.9 |
| CD49d | 14.1 ± 1.9 | 38.6 | 36.0 | 42.4 | 14.4 |
| CD62L | 1.3 ± 0.2 | 7.9 | 1.3 | 1.2 | 1.2 |
| CXCR4 | 53.5 ± 27.8 | 121.0 | 56.4 | 42.4 | 6.3 |
| CXCR5 | 35.4 ± 5.9 | 14.0 | 10.7 | 6.0 | 1.0 |
| CXCR3 | 2.0 ± 0.5 | 1.1 | 1.3 | 1.1 | 1.8 |
| MFIR . | MCL patients (n = 6) . | SP-53 . | MINO . | JeKo-1 . | Granta 519 . |
|---|---|---|---|---|---|
| CD44 | 42.5 ± 9.5 | 64.5 | 39.0 | 4.2 | 47.9 |
| CD49d | 14.1 ± 1.9 | 38.6 | 36.0 | 42.4 | 14.4 |
| CD62L | 1.3 ± 0.2 | 7.9 | 1.3 | 1.2 | 1.2 |
| CXCR4 | 53.5 ± 27.8 | 121.0 | 56.4 | 42.4 | 6.3 |
| CXCR5 | 35.4 ± 5.9 | 14.0 | 10.7 | 6.0 | 1.0 |
| CXCR3 | 2.0 ± 0.5 | 1.1 | 1.3 | 1.1 | 1.8 |
Phenotypic characteristics of MCL cells presented as mean fluorescence intensity ratio (MFIR) for major migration-related molecules. Gating on CD19-expressing cells identified MCL cells. Patient data shown are mean ± SEM values of 6 experiments with MCL cells from different patients.